2018
Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision
Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, Springer SA. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Substance Use & Misuse 2018, 53: 1519-1528. PMID: 29333954, PMCID: PMC6432769, DOI: 10.1080/10826084.2017.1416400.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Mood disordersBipolar disorderOpioid usersAddiction Severity Index-LiteOpioid use treatmentCriminal justice supervisionOpioid-dependent individualsSelf-reported mood disordersOpioid-dependent populationsComprehensive psychiatric careAdverse health consequencesLarger parent studyLifetime suicide attemptsHigh rateQuestionnaire-9Positive screenJustice-involved individualsSevere depressionTreatment utilizationGeneral U.S.Psychiatric careControl trialParent studyPsychiatric disorders
2007
Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases
Bruce RD, Altice FL. Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal Of Drug And Alcohol Abuse 2007, 33: 869-874. PMID: 17994482, DOI: 10.1080/00952990701653875.Peer-Reviewed Original ResearchConceptsHepatitis C virusAcute hepatitis C infectionHepatitis C infectionBuprenorphine treatmentC infectionChronic viral illnessesSafety of buprenorphineAcute HCV infectionBuprenorphine/naloxoneOpiate substitution therapyOpioid-dependent patientsOpiate substitution treatmentLaboratory evaluationChronic hepatitisElevated transaminasesHCV infectionLiver transaminasesViral illnessCase seriesSubstitution therapyC virusSubstitution treatmentBuprenorphinePatientsTransaminase